<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01140893</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT N° 2009-016384-11</org_study_id>
    <nct_id>NCT01140893</nct_id>
  </id_info>
  <brief_title>Effects of Exenatide on Glycemic Control and Weight in Continuous Subcutaneous Insulin Infusion (CSII) Type 2 Treated Patients With Type 2 Diabetes</brief_title>
  <acronym>EXEPUMP</acronym>
  <official_title>Effects of EXEnatide on Glycemic Control and Weight Over 26 Weeks in Continuous Subcutaneous Insulin Infusion (CSII) Treated Patients With Type 2 Diabetes : a Phase 2/3 Double Blind randoMized Placebo-controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Caen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether exenatide is effective to improve glycemic
      control among type 2 diabetic patients treated by insulin pump therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2010</start_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline to 6 months of centrally measured HbA1c</measure>
    <time_frame>baseline to 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in weight, BMI, waist circumference, 6 points glucose profile, insulin doses, % of daily use of insulin as basal rate, % of daily use of insulin as bolus, quality of life questionnaire</measure>
    <time_frame>baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean blood glucose value</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>occurrence of hyperglycemia above 190 mg/dl expressed as Area under the Curve (high) above 190 mg/dl (10.5 mmol/l), occurrence of hypoglycemia below 70 mg/dl (3.9 mmol/l) expressed as Area Under the Curve (low) below 70 mg/dl, glycemic variability (MAGE index).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>exenatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>55 subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>55 subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide</intervention_name>
    <description>Research drug (exenatide or placebo), will begin at V0, after randomization. The initial dosage for the first month will be 5 µg SC BID. Injections can be administered at any time within the 60 minute period before the morning and evening meal.
From V1, research drug will be titrated from 5 to 10 µg SC BID. If gastro-intestinal adverse effects occur with 10 µg SC BID, the dosage will be back-titrated to 5 µg SC BID. Thus, the higher research drug dosage tolerated will be used during the study time.</description>
    <arm_group_label>exenatide</arm_group_label>
    <other_name>Exenatide = BYETTA (R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women aged 35 to 70

          -  Type 2 diabetes diagnosed for at least 12 months, according the criteria of the
             American Diabetes Association :

               -  presence of classic symptoms of diabetes mellitus with unequivocal elevation of
                  plasma glucose (2-hour post-prandial or random glucose &gt;200 mg/dL) or

               -  fasting plasma glucose elevation on more than 1 occasion &gt; 125 mg/dL or

               -  patient currently undergoing pharmacological and/or non-pharmacological treatment
                  for diabetes mellitus

          -  CSII treatment using a rapid analog for at least 6 month (CSII being initiated in
             patients with HbA1c &gt; 8 % despite a well-conducted MDI trial using a 2 to 5 daily
             injection regimen)

          -  HbA1c ≥ 7,5% and ≤ 10 %

          -  BMI ≥ 25 and ≤ 45

          -  Stable body weight (≤10% variation) during the 3 last months

        Exclusion Criteria:

          -  Type 1 diabetes assessed by positive anti-GAD65 or anti-insulin or anti-IA2 antibodies

          -  Monogenic diabetes (MODY, mitochondrial diabetes…)

          -  Current treatment with OHA (OHA ought to be interrupted at least two months prior to
             inclusion in the study)

          -  Current treatment specifically addressed for weight lost (orlistat, sibutramine,
             rimonabant may be interrupted at least 3 months prior to inclusion in the study)

          -  Use of corticosteroid therapy for more than 10 days within the 3-past months, or
             patient who ought to be treated by corticosteroid during the study period

          -  Clinically significant hepatic disease

          -  Documented gastroparesis, or current use of drugs that directly affect
             gastrointestinal motility, or any significant abdominal disease that may increase the
             risk of adverse gastrointestinal effects induced by exenatide

          -  Kidney failure (MDRD less than 50 ml/min)

          -  Pregnancy/breastfeeding

          -  Any social and/or mental condition rendering the subject unable to understand the
             scope and possible consequences of the study

          -  Concurrent enrolment in another clinical trial

          -  Geographically inaccessible for follow-up visits required by protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael JOUBERT, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Endocrinology Unit, University Hospital of Caen, FRANCE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yves REZNIK, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Endocrinology Unit, University Hospital of Caen, FRANCE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Joubert, MD</last_name>
    <email>joubert-m@chu-caen.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yves Reznik, MD</last_name>
    <email>reznik-y@chu-caen.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Endocrinology Unit and Clinical Research Center Basse Normandie, University Hospital of Caen</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+33 2 31 06 45 75</phone>
    </contact>
    <investigator>
      <last_name>Michael JOUBERT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yves REZNIK, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CERIDT</name>
      <address>
        <city>Corbeil-Essonne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume Charpentier, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Endocrinology Unit</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nathalie Jeandidier, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2010</study_first_submitted>
  <study_first_submitted_qc>June 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2010</study_first_posted>
  <last_update_submitted>August 22, 2016</last_update_submitted>
  <last_update_submitted_qc>August 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 diabetes</keyword>
  <keyword>CSII</keyword>
  <keyword>Exenatide</keyword>
  <keyword>Double Blind Placebo Controlled Study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

